10-Q: TRxADE HEALTH, INC. Reports Q3 2023 Results, Completes Superlatus Merger and Faces Going Concern Challenges

TRxADE HEALTH, INC. reported its third quarter 2023 results, highlighted by the completion of the Superlatus merger, but also noted significant losses and concerns about its ability to continue as a going concern.

Summary

• TRxADE HEALTH, INC. reported a net loss of $3.5 million for the third quarter of 2023, and a net loss of $6.1 million for the nine months ended September 30, 2023.
• The company completed a merger with Superlatus, Inc. on July 31, 2023, acquiring 100% of its stock.
• The merger consideration was adjusted on January 8, 2024, to 136,441 shares of common stock and 15,759 shares of Series B Preferred Stock.
• TRxADE sold its subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC, on August 22, 2023, resulting in a loss of $3.2 million.
• The company acquired The Urgent Company, Inc. on September 27, 2023, for a $3.15 million promissory note.
• The company's cash balance was $34,031 as of September 30, 2023, down from $1,094,891 at the end of 2022.
• The company has a working capital deficit of $3.5 million and a retained deficit of $21.5 million.
• There is substantial doubt about the company's ability to continue as a going concern due to limited financial resources and the need for additional capital.
• The company's revenue for the third quarter was $2.06 million, consistent with the same period in 2022, while revenue for the nine months ended September 30, 2023 was $5.9 million, down from $8.0 million in 2022.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, a low cash balance, and a going concern warning. While there are some positive developments like the merger and acquisition, the overall sentiment is negative due to the company's financial instability and the risks it faces.

Positives

• Gross profit increased to 83% for the three months ended September 30, 2023, compared to 67% for the same period in 2022.
• The company completed the merger with Superlatus, Inc., expanding its business into food technology.
• The company acquired The Urgent Company, Inc., which is expected to enhance the company's production of sustainable food products.

Negatives

• The company's cash balance decreased significantly to $34,031 as of September 30, 2023.
• The company reported a net loss of $3.5 million for the third quarter of 2023 and $6.1 million for the nine months ended September 30, 2023.
• The company has a working capital deficit of $3.5 million and a retained deficit of $21.5 million.
• The company sold Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC, resulting in a $3.2 million loss.
• The company's revenue for the nine months ended September 30, 2023, decreased by 26% compared to the same period in 2022.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company has limited financial resources and needs to raise additional capital to support ongoing operations.
• The company's ability to continue as a going concern is in doubt due to its financial condition.
• The company may not be able to obtain additional financing on favorable terms, if at all.
• The company's operations may not generate significant positive cash flow.
• The company's stock may be delisted from the Nasdaq Capital Market if it fails to meet continued listing standards.
• The company is subject to risks related to inflation, supply chain disruptions, and geopolitical instability.
• The company is subject to risks related to the Receivables Agreement, which could adversely affect cash flows.

Future Outlook

The company's primary objectives for the remainder of 2023 are to increase its client base and revenue on its Trxade Inc. and Trxade Prime platforms, and to complete potential strategic transactions of its business-to-consumer subsidiaries. The company will also need to raise additional capital to support its operations.

Management Comments

• Management believes that preparing and implementing sufficient written policies and checklists will remedy the material weaknesses in internal controls.
• Management is committed to improving the company's financial organization.

Industry Context

The company operates in the healthcare and food technology industries, which are both subject to rapid changes and competition. The company's focus on digitalizing the retail pharmacy and health services experience aligns with broader trends in the healthcare industry. The merger with Superlatus and acquisition of The Urgent Company, Inc. reflects a diversification strategy into the food technology sector.

Comparison to Industry Standards

• The company's financial performance, particularly the significant losses and negative cash flow, is concerning when compared to industry benchmarks.
• The company's gross profit margin of 83% for the three months ended September 30, 2023, is relatively high, but this is offset by high operating expenses.
• The company's reliance on debt financing and the need for additional capital raises concerns about its long-term financial sustainability.
• The company's challenges in maintaining its Nasdaq listing are not uncommon for smaller companies, but the severity of the issues raises concerns about its financial health.
• The company's diversification into food technology is a strategic move, but it is too early to assess its success compared to established players in that sector.

Legal Proceedings

• The company is involved in ongoing litigation with Studebaker Defense Group, LLC, Sandwave Group Dsn Bhd, Crecom Burj Group SDN BHD, and GSG PPE, LLC.
• The company believes that the resolution of currently pending matters will not individually or in the aggregate have a material adverse effect on our financial condition or results of operations.

Related Party Transactions

• The company entered into a relationship with Scietech, LLC, where a 31% investor is the spouse of the interim CFO, Prashant Patel.
• The company had a relationship with Exchange Health, LLC, which resulted in the formation of SOSRx, LLC, which was later terminated.

Stakeholder Impact

• Shareholders face the risk of significant dilution from potential equity raises and the possibility of losing their investment if the company cannot continue as a going concern.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers may experience disruptions in service or product availability if the company faces financial difficulties.
• Suppliers may be affected by the company's financial instability and potential inability to pay its obligations.
• Creditors face the risk of not being repaid if the company's financial situation worsens.

Next Steps

• The company will take steps to increase its client base and operational revenue on its Trxade Inc. and Trxade Prime platforms.
• The company will complete potential strategic transactions of its business-to-consumer subsidiaries.
• The company will need to raise additional capital to support its operations.

Key Dates

Keywords

Merger, Acquisition, Financial Results, Going Concern, Pharmaceuticals, Food Technology, Loss, Revenue, Debt, Equity, Nasdaq, Working Capital, Promissory Note